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We used the bone marrow DNA strand breaks, micronucleus formations, spermatocyte chromosomal aberrations, and sperm
characteristic assays to investigate the chromosomal instability in somatic and germinal cells of diabetic rats treated with multiple
doses of naringin. The obtained results revealed that naringin was neither cytotoxic nor genotoxic for the rats at all tested
doses. Moreover, naringin signiﬁcantly reduced the diabetes-induced chromosomal instability in somatic and germinal cells
in a dose-dependent manner. In addition, diabetes induced marked biochemical alterations characteristic of oxidative stress
includingenhancedlipidperoxidation,accumulationofoxidizedglutathione,reductioninreducedglutathione,andaccumulation
of intracellular reactive oxygen species. Treatment with naringin ameliorated these biochemical markers dose-dependently.
In conclusion, naringin confers an appealing protective eﬀect against diabetes-induced chromosomal instability towards rat
somatic and germinal cells which might be explained partially via diminishing the de novo free radical generation induced by
hyperglycemia. Thus, naringin might be a good candidate to reduce genotoxic risk associated with hyperglycemia and may
providedecreases in the development of secondary malignancy and abnormal reproductive outcomes risks, which seems especially
important for diabetic patients.
1.Introduction
Diabetes mellitus is a serious health problem aﬀecting
millions of individuals worldwide. By the year 2025, the
WorldHealthOrganization(WHO)predictsthat300million
people will have diabetes mellitus [1]. Oxidative stress is
thought to play a signiﬁcant role in the aetiopathology of
a wide variety of diseases such as chronic inﬂammation,
atherosclerosis, and cancer [2]. It can be also associated
with type II diabetes mellitus and reactive oxygen species
produced during this stress may cause DNA damage [3, 4].
Moreover, individuals with diabetes mellitus have reduced
antioxidant defence capacity [5]. DNA damage and repair
play a major role in neoplastic transformation, because
mutations in DNA repair genes can be directly related with
cancer and the eﬃcacy of DNA repair may determine the
susceptibility to carcinogenesis [6]. The oxidative damage to
the germinal cells is considered to be the leading cause for
the various reproductive related complications resulting in
infertility and other congenital and developmental defects
[7]. It has been demonstrated that diabetes mellitus is
associated with elevated level of oxidative DNA damage
and with the increased susceptibility to mutagens and
the decreased eﬃcacy of DNA repair [8, 9]. This can
contributetothechromosomalinstabilityindiabeticsand,in
consequence, to cancer [10]. Epidemiological data suggest a
positive correlation between diabetes mellitus and increased
cancer risk, but the mechanism underlying this correlation
and precise relationship between chronic hyperglycemia and
c a n c e ra r es t i l lo b s c u r e[ 11].
Treatment of diabetes mellitus and its complications
in the recent context has focused on the usage of plant
extracts and their constituents. The WHO had estimated
that approximately 80% of the Earth’s inhabitants rely on
traditional medicine for their primary health care needs, and
most of this therapy involves the use of plant extracts or their
activecomponents[12].Grapefruitis partofthedietinmost2 Oxidative Medicine and Cellular Longevity
Table 1: DNA strand breaks in bone marrow of nondiabetic and diabetic rats 24 hours after the last treatment with the indicated doses of
naringin (4 weeks exposures, spaced 24 hours apart) (mean ± SD).




Nondiabetic control 14.0 ± 4.8 5.98 ± 1.15 1.96 ± 0.61 4.78 ± 1.23
Nondiabetic + naringin (25) 12.6 ± 4.77 5.76 ± 1.52 2.12 ± 0.43 4.14 ± 0.56
Nondiabetic + naringin (50) 11.8 ± 4.71 4.82 ± 1.76 1.98 ± 0.23 3.20 ± 0.73
Diabetes 27.2 ± 4.91∗ 14.2 ± 3.39∗ 4.72 ± 0.54∗∗ 9.44 ± 2.03∗
Diabetes + naringin (25) 18.6 ± 4.33a 8.08 ± 1.54b 2.98 ± 0.85a 5.82 ± 1.27b
Diabetes + naringin (50) 15.8 ± 3.96b 6.97 ± 1.53b 2.24 ± 0.7b 4.32 ± 1.18b
∗P < 0.05 and ∗∗P < 0.01 versus nondiabetic control (Kruskal-Wallis test followed by Dunn’s multiple comparisons test). aP<0.05 and bP<0.01 versus
diabetes alone (Mann-Whitney U test).
countries, where it is often consumed regularly as juice. The
chemical responsible for the characteristic sour ﬂavour of
the fruit is naringin, a ﬂavonone that is rapidly transformed
into naringenin by the action of the enzymes α-ramnosidase
and β-glucosidase [13]. Naringin exhibits various phar-
macological and therapeutic properties including action as
anticancer, anti-inﬂammatory, and cardioprotective activity
[14]. Moreover, naringin decreased blood glucose levels and
increased plasma insulin levels in streptozotocin-induced
diabetic rats [15, 16]. Like most ﬂavonoids, naringin has
metal chelating, antioxidant, and free radical scavenging
properties and has been reported to oﬀer some protection
against lipid peroxidation [17, 18].
Much interest has surrounded the role and use of
natural antioxidants as a mean of preventing oxidative
damage in diabetes mellitus with high oxidative stress.
In this context, our aim was to evaluate the potential
antigenotoxic utility of naringin against diabetes-induced
chromosomal instability towards rat somatic and germinal
cells and to elucidate the possible mechanism whereby
naringin mediates its beneﬁcial eﬀects. Collecting these data
might lead to focusing on development of novel antigeno-
toxic agents that are commonly consumed in human diet.
In laboratory animals, streptozotocin and alloxan show
selective cytoxicity in pancreatic β-cells and thus cause
both type I and type II diabetes mellitus. Diabetics and
experimental animal models exhibit high oxidative stress
due to persistent and chronic hyperglycemia, depleting the
activity of antioxidant defencesystem and thus promoting de
novo free radical generation [19]. Generated free radicals can
attack all types of macromolecules including DNA causing
chromosomal instability that may lead to mutagenesis or
carcinogenesis [20]. The somatic cell chromosomal insta-
bility was assessed by the bone marrow comet assay and
micronucleus test. Spermatocyte chromosomal analysis and
spermiograms examination were undertaken in the current
study as markers of germ cell chromosomal instability.
In addition, oxidative stress markers such as sperm lipid
peroxidation, oxidized glutathione (GSSG), reduced glu-
tathione (GSH) levels, and reactive oxygen species (ROS)
were assessed as a possible mechanism underlying this
amelioration.
Table 2: Frequencies of micronucleated polychromatic erythro-
cytes (% MNPCE) and mitotic activity (% PCE) in bone marrow
of nondiabetic and diabetic rats 24 hours after the last treatment
with the indicated doses of naringin (4 weeks exposures, spaced 24
hours apart) (mean ± SD).




Nondiabetic control 0.32 ± 0.08 48.4 ± 1.81
Nondiabetic + naringin (25) 0.30 ± 0.07 48.2 ± 2.16
Nondiabetic + naringin (50) 0.28 ± 0.08 49.0 ± 1.41
Diabetes 0.92 ± 0.13∗∗ 45.6 ± 3.97
Diabetes + naringin (25) 0.60 ± 0.12a 47.0 ± 2.54
Diabetes + naringin (50) 0.44 ± 0.11b 47.4 ± 2.40
∗∗P < 0.01 versus nondiabetic control (Kruskal-Wallis test followed by
Dunn’s multiple comparisons test). aP<0.05 and bP<0.01 versus diabetes
alone (Mann-Whitney U test).
2. Results
2.1. Eﬀe c to fN a r i n g i no nD i a b e t e s - I n d u c e dD N AS t r a n d
Breaks. The results of alkaline comet assay are shown in
Table 1. Naringin treatment did not exhibit any signiﬁcant
diﬀerence in the level of tail length, tail DNA, tail moment,
and olive tail moment compared to the solvent control at
either dose tested. The results revealed that diabetes causes
signiﬁcant increase in the level of all measured parameters in
comparison to those of the solvent control group. However,
when both doses of naringin were given to diabetic animals
for 4 weeks, decreased rates of DNA strand breaks were
signiﬁcantly observed and the higher dose of naringin gave
the more eﬀe c t i v er e d u c t i o ni na l lm e a s u r e dp a r a m e t e r s( P<
0.01).
2.2. Eﬀect of Naringin on Diabetes-Induced MNPCE. The
results of the MN test are presented in Table 2. Signiﬁcant
increaseinthefrequencyofMNPCEwasobservedindiabetic
rats compared to the solvent control group (P<0.01).
Naringin treatment did not exhibit any signiﬁcant diﬀerence
in the frequency of MNPCE compared to the solvent control
at both tested doses. With regard to the diabetic animalsOxidative Medicine and Cellular Longevity 3
treated with naringin, a weak protection was observed with
25mg/kg of naringin (P<0.05). With 50mg/kg, however,
naringin produced a clear signiﬁcant inhibitory eﬀect on
the MNPCE induced during diabetes in comparison to
the untreated diabetic rats (P<0.01). The results for the
rate of PCE:NCE are also presented in Table 2. It is shown
that no signiﬁcant decrease in the percent PCE was observed
when the bone marrow cells were sampled from diabetic rats
(P>0.05). Similarly, none of the tested doses of naringin
modiﬁed the ratio in comparison with the control group.
2.3. Eﬀe c to fN a r i n g i no nD i a b e t e s - I n d u c e dS p e r m a t o c y t e
Chromosomal Aberration. The results of the spermato-
cyte diakinesis-metaphase I analysis are shown in Table 3.
Naringin treatment did not exhibit any signiﬁcant diﬀerence
in the frequency of structural or numerical (polyploides)
chromosomal aberrations compared to the solvent control at
both tested doses. The results revealed that diabetes induced
aberrant primary spermatocytes, which are statistically sig-
niﬁcant (P<0.05) compared with that of the nondiabetic
control group. Nevertheless, at both doses tested, naringin
treatment reduced the total frequency of aberrant primary
spermatocytes in diabetic rats in comparison to untreated
diabetic group, and higher dose of naringin gave more
eﬀective reduction in the frequency of total chromosomal
aberrations (P<0.01). Moreover, the administration of
higher dose of naringin produced a response which was close
to the one observed with the solvent control.
2.4. Eﬀect of Naringin on Diabetes-Induced Alterations in
Spermatozoa Count and Abnormalities. The results of the
sperm cell experiments are shown in Table 4.T r e a t m e n to f
rats with naringin did not aﬀect the parameters studied as
compared to the nondiabetic control value at both tested
doses. Sperm count was signiﬁcantly decreased in untreated
diabetic animals as compared to the value observed in
the control group. Moreover, diabetes caused a signiﬁcant
increase in the percentage of abnormal sperm (P<0.05).
Treatment of rats with naringin for 4 weeks after diabetes
inductionincreasesthedecreasedpercentageofspermcount.
Moreover, the percentage of abnormal sperm was also
restoredwithnaringintreatmentandhigherdoseofnaringin
gave more amelioration (P<0.01).
2.5. Eﬀe c to fN a r i n g i no nD i a b e t e s - I n d u c e dS p e r mO x i d a t i v e
Stress. The eﬀect of naringin on the diabetes-induced oxida-
tivestressinratswasassessedbymeasuringspermMDAcon-
tent, GSH, GSSG levels, and ROS accumulation. The results
oftheseexperimentsarealsoshowninTable 4.Nosigniﬁcant
change in MDA content was observed in sperm cells after
naringin treatment compared to the control at both tested
doses.TheMDAcontentindiabeticanimalswassigniﬁcantly
increasedascomparedtocontrolgroup(P<0.05).Diabetes-
induced MDA formation was abrogated by naringin at the
two tested doses and decreased to level signiﬁcantly diﬀerent
from the level of MDA in untreated diabetic animals. Higher
dose of naringin gave more protection (P<0.01).
Sperm GSH and GSSG levels did not show any sig-
niﬁcant variation in naringin-treated animals compared to
the control. The GSH level observed in diabetic animals
was signiﬁcantly decreased, together with increase in GSSG
l e v e la sc o m p a r e dt ot h ec o n t r o lg r o u p( P<0.05), so
that GSH/GSSG ratio signiﬁcantly decreased, indicating
increased oxidative stress (P<0.05). Diabetic animals
treated with both doses of naringin showed a signiﬁcant
increase in GSH level over the untreated diabetic animals
and increased to level signiﬁcantly diﬀerent from the level of
GSH in the untreated diabetic rats. The GSSG level was also
signiﬁcantly decreased in diabetic animals treated with both
doses of naringin compared to untreated diabetic rats. Con-
sequently, the GSH/GSSG ratio was increased in naringin
treateddiabeticanimalsandwasstatisticallysigniﬁcantwhen
compared to the untreated diabetic rats. The maximum
increase in GSH/GSSG ratio was also observed in diabetic
animals treated with naringin 50mg/kg.
Sperm ROS production was evaluated by determining
the ﬂuorescent intensity of DCF. DCF ﬂuorescence level did
not show any signiﬁcant variation after treatment of rats
with both doses of naringin as compared to the control. The
sperm DCF ﬂuorescence level observed in diabetic animal
was signiﬁcantly increased by about 1.6-folds as compared
to the control (P<0.05). However, diabetes-induced
production of DCF ﬂuorescence was profoundly abrogated
by both doses of naringin and decreased to the level
signiﬁcantly diﬀerent from the level of DCF ﬂuorescence in
untreated diabetic animals (P<0.01).
3. Discussion
Diabetes mellitus itself is not responsible for a high mortality
and morbidity among diabetic patients. They are caused
mainly by its complications, ﬁrst of all coronary heart
disease, which are, at least in part, consequences of oxidative
stressassociatedwithdiabetes.Somereportssuggestalsothat
diabetes can be associated with cancer, but the mechanism
underlying this association is unclear. A previous study
demonstrated that diabetes was linked with the elevated
level of oxidative DNA damage, the increased susceptibility
to mutagens, and the decreased eﬃcacy of DNA repair
[8]. Because oxidative DNA damage may contribute to
cancer promotion and progression, it can be considered
as an element of the link between diabetes and cancer
[9]. In this context, using natural antioxidative compounds
would have a beneﬁt in preventing diabetes oxidative stress-
related consequences. Importantly, certain antioxidants are
known to have genotoxic or carcinogenic potentials [21,
22]; however, the treatment with naringin, in the present
study, was devoid of any genotoxicity and/or cytotoxicity
in nondiabetic and diabetic rats. Moreover, treatment with
naringin was found to protect against diabetes-induced
increase of somatic and germinal chromosomal instabil-
ity. These observations conﬁrm earlier studies in which
naringin was reported to prevent radiation or lomeﬂoxacin-
induced chromosomal instability in animal models [23,
24].4 Oxidative Medicine and Cellular Longevity
Table 3: Frequency of spermatocyte chromosomal aberrations in testes of nondiabetic and diabetic rats 24 hours after the last treatment
with the indicated doses of naringin (4 weeks exposures, spaced 24 hours apart) (mean ± SD).
Treatment groups (mg/kg)




univalents F/B Polyploidy MV
Nondiabetic control 7 4 2 0 1 2.8 ± 0.44
Nondiabetic + naringin (25) 6 3 1 — 1 2.4 ± 0.89
Nondiabetic + naringin (50) 5 6 1 0 1 2.6 ± 0.89
Diabetes 22 18 3 2 3 9.60 ± 1.51∗
Diabetes + naringin (25) 13 10 2 1 1 5.40 ± 1.81a
Diabetes + naringin (50) 6 5 2 2 1 3.20 ± 1.09b
∗P < 0.05, versus nondiabetic control (Kruskal-Wallis test followed by Dunn’s multiple comparisons test). aP<0.05 and bP<0.01 versus diabetes alone
(Mann-Whitney U test). F: fragments; B: breaks; MV: multivalents having a chain of four chromosomes.
Table 4: Frequencies of sperm count, abnormalities, ROS, GSSG, GSH, GSSG/GSH ratio, and MDA of nondiabetic and diabetic rats 24



















control 46.8 ± 6.7 2.2 ± 0.8 12.6 ± 1.8 1.8 ± 0.4 0.26 ± 0.05 7.4 ± 2.5 100.0 ± 7.4
Nondiabetic +
naringin (25) 49.0 ± 5.7 1.8 ± 0.8 11.4 ± 3.2 1.9 ± 0.4 0.24 ± 0.05 8.1 ± 2.0 95.4 ± 8.5
Nondiabetic +
naringin (50) 51.0 ± 7.3 1.6 ± 0.54 10.4 ± 2.7 2.2 ± 0.5 0.25 ± 0.07 8.3 ± 2.8 93.2 ± 9.3
Diabetes 34.8 ± 3.3∗ 6.4 ± 1.3∗ 19.6 ± 3.7∗ 0.8 ± 0.2∗ 0.36 ± 0.04∗ 2.4 ± 0.8 160.8 ± 15.5∗
Diabetes +
naringin (25) 41.0 ±4.2a 4.6 ±0.5a 13.6 ±3.5b 1.5 ±0.18b 0.26 ±0.05a 6.0 ±1.5b 125.4 ±14.9b
Diabetes +
naringin (50) 46.0 ± 3.6b 2.2 ±0.8b 10.8 ±2.6b 1.8 ±0.15b 0.22 ±0.05b 8.5 ±2.1b 106.4 ±8.7b
∗P<0.05 versus nondiabetic control (Kruskal-Wallis test followed by Dunn’s multiple comparisons test), aP<0.05, bP<0.01 versus diabetes alone (Mann-
Whitney U test). MDA: malondialdehyde; GSH: reduced glutathione; GSSG: oxidized glutathione; ROS: reactive oxygen species.
The genotoxic eﬀects of the diabetogenic agent strepto-
zotocin observed in the current study are in agreement with
results obtained from previous animal studies [25, 26]. The
observed chromosomal instability in the rats with experi-
mental diabetes could be explained by many physiological
changes caused by the pancreatic β-cell destruction induced
by streptozotocin. This damage may trigger inﬂammatory
processes, as well as hyperglycaemia-induced oxidative stress
[27], that may be suﬃcient to increase the chromosomal
damage. A prolonged diabetic state of rats before starting
the sampling has produced high amounts of additional
damage in the diabetic rats; this could be due to the
metabolic alterations that occurred as a result of diabetes,
as it happens in humans with long-term hyperglycaemia
who acquire diverse vascular and renal dysfunctions. These
pathologies may cause inﬂammatory reactions that also are
associated with increased free radical production and, as a
consequence, with increased DNA damage [28, 29]. In fact,
elevated levels of DNA damage evaluated with the sister
chromatid exchange, MN, and alkaline comet assay were
reported in patients with type II diabetes mellitus [8, 30, 31].
It is becoming increasingly evident that an increased rate of
DNA damage or chromosome breakage in somatic cells is an
important risk factor for cancer [32].
Reproductive disturbances in diabetic males are well
established and diabetes is the most common cause of
erectile dysfunction in men. Moreover, poor semen quality
has also been reported in diabetic men, including sperm
concentration and increased abnormal sperm morphology
[33]. In animal models of diabetes, induced by either
streptozotocin or alloxan, earlier works have demonstrated
v a r i o u sm a l er e p r o d u c t i v ed y s f u n c t i o n sb o t hs t r u c t u r a l l y
and functionally [34, 35]. In the current study we have
ascertained the germ cell genotoxicity in terms of incidence
of spermatocyte chromosomal aberration, sperm count,
and abnormal sperm morphology. Marked alteration in
these studied parameters during the progressive phase of
diabetes possibly conﬁrms that the diabetes induction has a
signiﬁcanteﬀectonspermatogenesis,spermmaturation,and
development during storage and transit. Higher incidence
of spermatocyte chromosomal aberration, reduced sperm
counts and higher abnormal sperm during the progressive
phase of diabetes may be interpreted as a combined eﬀect
of reduced leydig cell function (as evidenced by reducedOxidative Medicine and Cellular Longevity 5
testosterone levels in serum/testis) and diabetes-associated
oxidative stress [36]. The current results conﬁrm earlier
studies in which elevated genotoxicity and oxidative stress
were observed in the spermatozoa of diabetic rats [26, 37].
Induction and repair of DNA strand breaks and alkali-
labile sites by streptozotocin was analyzed by several authors.
Mossman et al. [38] showed that streptozotocin induces
DNA single-strand breaks in a rat insulinoma cell line
(RINr 38) and that these lesions can be repaired in a time-
dependentmanner,withmostrepaircompletedby24hpost-
exposure to streptozotocin. Using the same cell line, Pet-
tepher et al. [39] demonstrated that streptozotocin induces
alkali-labile sites in a dose-dependent fashion within the
mitochondrial DNA and that these lesions can be repaired.
Pettepher et al. [39] found that 8h after exposure to the
antibiotic, 55% of the lesions induced in the mitochondrial
DNA were removed. The level of repair increased to 70%
after 24h.
On the other hand, in our study the diabetic rats were
euthanized approximately 4 weeks after the streptozotocin
administration and the frequencies of chromosomal insta-
bility and oxidative stress markers were signiﬁcantly higher
in those diabetic rats as compared to the control. Thus,
streptozotocin per se was not responsible for the increased
levels of chromosomal instability in diabetic rats. This fact
m a yb ej u s t i ﬁ e db yJ u n o de ta l .[ 40]i na na t t e m p tt o
follow the metabolism of synthesized streptozotocin, (1-
14C)-streptozotocin, (2-14C)-streptozotocin, and (3-methyl
14C)-streptozotocin (speciﬁc activity 1–2.7μCi/mg) in rats.
Firstly, the urine collected during the ﬁrst 1h drug con-
tained the highest proportion of the injected radioactivity
(34% with 3-methyl 14C)-streptozotocin, 40% each with (1-
14C)-streptozotocin and (2-14C)-streptozotocin. This larger
proportion suggested that either unchanged streptozotocin
or its metabolites were rapidly eliminated from the body.
Therefore, the increased levels of chromosomal instability
in somatic and germinal cells in diabetic rats are likely due
to the oxidative stress resulting from hyperglycemia. Hyper-
glycemia, a well-recognized pathogenetic factor of long-term
complications in diabetes mellitus, not only generates more
ROS but also attenuates antioxidative mechanisms through
glycation of the scavenging enzymes [41].
The mechanism of inhibition of diabetes-induced chro-
mosomal instability in the present study is not clearly
understood. One possible explanation is that treatment with
naringin would allow interception of free radicals generated
by diabetes before they reach DNA. In the present work, in
order to evaluate whether the observed antigenotoxic eﬀect
was due to an enhancement of the scavenger of free radicals
generated by diabetes, oxidative stress markers such as lipid
peroxidation, GSH/GSSG ratio and ROS accumulation, were
evaluated4weeksafterdiabetesinduction.Thepresentstudy
demonstrates that naringin reduced the diabetes-induced
sperm lipid peroxidation and ROS accumulation and pre-
vented the reduction in GSH/GSSG ratio signiﬁcantly. The
increasedGSHlevelsuggeststhatprotectionbynaringinmay
be mediated through the modulation of cellular antioxidant
levels. These observations conﬁrm earlier studies in which
naringin was reported to scavenge free radicals and lipid
peroxides [15, 24]. Thus, scavenging of these free radicals by
naringin seems to be an important mechanism against the
hyperglycemia-induced chromosomal instability.
The detailed mechanisms of the naringin antigenotoxic
action remain to be investigated in future. In the current
study, we tried to conﬁrm one possible mechanism of
naringin’s antigenotoxic action, that is, inhibition of free
radicalgeneration.Theresultsdemonstratedthatfreeradical
generation by hyperglycemia was considerably inhibited by
the treatment with naringin. In addition, analysis of gene
expression for genes related to oxidative stress, measure-
ments of more sensitive markers for lipid peroxidation, or
oxidative DNA damage and immunocytochemical detection
for these markers might be interesting and might provide
molecular insights for the protective eﬀect of naringin
against chromosomal instability induced by hyperglycemia.
However, at present diabetic patients who consume naringin
as part of their diet should also consider its additional, bene-
ﬁcial eﬀect—a possible decrease in chromosomal instability,
which seems especially important for diabetic patients.
4.MaterialsandMethods
4.1. Animals. Adult Wistar albino male rats weighing 250–
300g (10–12 weeks old) were obtained from Experimental
Animal Care Center, College of Pharmacy, King Saud
University. The animals were maintained under standard
conditions of humidity, temperature (20 ± 2◦C), and light
(12-h light/12-h dark). They were fed with a standard
rats pellet diet and had free access to water. All animal
experimentation described in the manuscript was conducted
in accordance with accepted standards of humane animal
care in accordance with the NIH guidelines and the legal
requirements in Kingdom of Saudi Arabia.
4.2. Drugs. Naringin and streptozotocin were purchased
from Sigma (Sigma-Aldrich St. Louis, MO, USA). Streptozo-
tocin was dissolved in freshly prepared sodium citrate buﬀer
(pH 4.4) while naringin was dissolved in distilled water
and administered by gavage following preparation. Control
animals were received equal amounts of distilled water. All
other chemicals were of the ﬁnest analytical grade.
4.3. Induction of Diabetes in Rats. The overnight fasted rats
were made diabetic by a single intraperitoneal injection of
freshly prepared streptozotocin (65mg/kg) in citrate buﬀer
i nav o l u m eo f1 m L / k g .T h r e ed a y sa f t e rs t r e p t o z o t o c i n
administration, the blood glucose level of each rat was
determined. Rats with blood glucose levels of >350mg/dL
were considered diabetic and included in the study. Treat-
ment with naringin was started on the third day after
streptozotocin injection (i.e., after the estimation of blood
glucose).
4.4. Experimental Design. Six groups of 5 adult rats were
used. Three groups of them were ﬁrst made diabetic
as described above. When diabetes was conﬁrmed, two6 Oxidative Medicine and Cellular Longevity
groups were given 25 or 50mg/kg naringin orally using
an intragastric tube daily for a period of 4 weeks and the
other two nondiabetic groups were also daily received by
oral intragastric tube doses of 25 or 50mg/kg naringin
for 4 weeks. The doses of naringin were selected on the
basis of its the antihyperglycemic and antioxidant eﬀects
in streptozotocin-induced diabetes in male Wistar rats
[16]. Untreated nondiabetic and diabetic groups were also
included in the experiment. The animals were killed by
cervical dislocation under light anesthesia at week 4 post
naringin treatments, then bone marrow cells, testes, and
sperm cells were sampled. Naringin has been described
t ob ep r e s e n ti ng r a p e f r u i tj u i c ea ta b o u t1 0 1 m g / l i t r e
[42]. Upon conversion of animal dose to the equivalent
human dose (human dose (mg/kg) = rat dose (mg/kg) ×
(6/37)), a dose of 50mg/kg naringin in rats corresponded
to 8.1mg/kg in humans. Accordingly, for an average person
weighing 60kg, 486.5mg naringin would be needed. Based
on the previously mentioned concentration range, 486.5mg
naringin would be contained in 0.5 litre of grapefruit
juice.
4.5. Detection of Bone Marrow DNA Strand Breaks. Rats were
sacriﬁced by cervical dislocation, bone marrow cells from
one femur were collected in tubes containing ice-cold PBS
(Ca2+ and Mg2+ free, pH 7.4), and DNA strand breaks were
studied by alkaline single cell gel electrophoresis (alkaline
comet assay) according to the guidelines of Tice et al.
[43] with slight modiﬁcations as previously described [44].
The slides were stained with ethidium bromide (20μg/mL)
and studied using a ﬂuorescent microscope (Nikon, Japan)
equipped with appropriate ﬁlter. Fifty individual cells were
selected for calculations for each analysis; all experiments
were carried out at least three times, each with two parallel
slides per animal. Single cells were analyzed with TriTek
CometScore version 1.5 software. The parameters studied to
access the DNA damage were the tail length (μm), tail DNA
(%), tail moment (arbitrary units), and olive tail moment
(arbitrary units).
4.6. Bone Marrow Micronucleus Test. The remaining femur
was used for estimation of micronuclei (MN) frequencies
and mitotic activity. The bone marrow cells were collected
in tubes containing foetal calf serum and centrifuged for
10 minutes at 1,100rpm. The pellets were resuspended
in a small volume of foetal calf serum for smear prepa-
ration. Two smears of bone marrow were prepared from
each rat. After air drying, the smears were coded and
stained by May-Gruenwald/Giemsa as described previously
[45]. From each animal, 1,000 polychromatic erythrocytes
(PCEs) and 1,000 normochromatic erythrocytes (NCEs)
were examined for the presence of MN under 1,000x
magniﬁcations using a Nikon microscope. In addition the
number of PCEs among 1,000 NCE per animal was recorded
to evaluate bone marrow suppression, mitotic activity. The
value was expressed as % PCEs of the total erythrocyte
counts to determine the reduction of erythroblast prolifer-
ation.
4.7. Primary Spermatocyte Chromosomal Analysis. Immedi-
atelyaftercervicaldislocation,bothtestesusedwereremoved
and placed in 2.2% isotonic tri-sodium citrate solution. The
tunica albugenia was peeled out and somniferous tubules
were teased to form a cell suspension. The suspension was
centrifuged for 5 minutes at 1,000rpm and the pellet was
resuspended in 1.1% hypotonic tri-sodium citrate solution
for 20 minutes at room temperature. After centrifugation the
supernatant was discarded and the pellets were resuspended
in Carnoy’s ﬁxative. Two to three changes of ﬁxative were
required before the preparation of slides. Finally, the cells
w e r es u s p e n d e di n1 m Lo fﬁ x a t i v ea n db u r s to p e no na
clean slide to release chromosomes. At least four slides
were made for each animal and allowed to dry overnight.
The coded slides were stained with giemsa and scored
as detailed earlier [46]. Hundred well-spread diakinesis-
metaphase I cells per animal were analyzed under bright
ﬁeld microscope for chromosomal aberrations. The types of
aberrationsrecordedindiakinesis-metaphaseIcellsincluded
univalents, fragments, breaks, polyploids, and multivalents
having a chain of four chromosomes. The percentage of total
c h r o m o s o m a la b e r r a t i o n sf o re a c hg r o u pw a sc a l c u l a t e d .
4.8. Cauda Epididymal Spermatozoa Evaluation. For sperm
characteristic analysis, one epididymal content of each rat
was collected to estimate the sperm abnormalities and sperm
counts. Immediately after cervical dislocation, one caudae
epididyme of each animal was dissected and incisions were
made. Then the epididymes were placed individually into
tubes ﬁlled with 3mL of fetal calf serum. The tubes were
placed on an Eppendorf incubator at 32◦Cf o r3 0m i n u t e s
to allow the sperm to actively leave the epididymes. The
tissue residuals were removed from the tubes. The slides
were stained and examined by bright ﬁeld microscope with
an oil immersion lens according to published protocol [47].
Two and half thousand sperms per group were scored and
the abnormalities were categorized as close as to those
d e s c r i b e db yW y r o b e ka n dB r u c e[ 47]. Abnormal sperms
had forms readily recognizable as amorphous, beak, without
hook, triangular, banana-shaped, tail abnormality, dwarf,
and giant. Sperm count was determined under the light
microscopeusingaNeubauerhematocytometeraccordingto
the World Health Organization manual for the examination
of human semen [48], and two counts per animal were
averaged.
4.9. Determination of Oxidative Stress Markers in Sperm Cells.
To study the eﬀect of naringin on the oxidative damage
induced by diabetes, sperm cells were collected from the
remaining caudae epididymes for estimation of lipid peroxi-
dation,GSH,GSSG,andROSgeneration.Malonodialdehyde
(MDA) generated by lipid peroxidation was quantiﬁed in
the sperm cells according to the method of Ohkawa et
al. [49] based on thiobarbituric acid reactivity. The MDA
levels of the samples were calculated from the standard
curve using the 1,1,3,3-tetramethoxypropane as the standard
and expressed as nmol/mg protein. GSH was assayed withOxidative Medicine and Cellular Longevity 7
5,5 -dithiobis(2-nitrobenzoic acid)(DTNB)accordingtothe
protocol described by Ellman [50]. GSSG was assayed with
DTNB, glutathione reductase, and nicotinamide adenine
dinucleotide phosphate as described previously [51]. The
concentrations of GSH and GSSG were calculated from
standard curves that were obtained from freshly prepared
standard solutions of GSH and GSSG, respectively, and
expressed as μg/mg protein. The value obtained for GSH
was divided by the GSSG value to get the GSH/GSSG ratio.
Protein quantitative was carried out by the method of Lowry
et al. [52] using bovine serum albumin as a standard.
The generation of intracellular ROS was evaluated based
on the intracellular peroxide-dependent oxidation of 2 ,7 -
dichlorodihydroﬂuorescein diacetate (DCFH-DA) to form
a ﬂuorescent compound, 2 ,7 -dichloroﬂuorescein (DCF)
with some modiﬁcations as previously described [53]. The
sperm cells were collected in tubes containing 1.5mL fetal
calf serum and then centrifuged and washed with ice-cold
PBS buﬀer (pH 7.4). The sperm cells were harvested by
centrifugation, washed twice with cold PBS, and ﬁnally
resuspended in PBS buﬀer. 200μLs p e r mc e l l s( 2× 105)
were incubated with 200μL of DCFH-DA (0.4μM) for 60
minutes at 37◦C in dark. The ﬂuorescence intensity was
monitored with a FLUOstar OMEGA microplate reader
(BMG LABTECH Ltd., Germany) from an excitation wave-
length of 485nm and an emission wavelength of 520nm.
Results were expressed as fold of nondiabetic control.
4.10.DataAnalysis. Datawereexpressedasthemean ±stan-
dard deviation (SD) of the means. The data were analyzed
by employing nonparametric tests, Mann-Whitney U test, or
Kruskal-WallistestfollowedbyDunn’smultiplecomparisons
test. Results were considered signiﬁcantly diﬀerent if the P
value was less than 0.05.
Abbreviations
ROS: Reactive oxygen species
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